Absci plans Phase 2 trial of ABS-201 for endometriosis in mid-2027

September 24, 2026 8:00 AM

Absci Corporation (Nasdaq: ABSI) announced details of its planned Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found